The Role of New and Emerging Treatment Options for Type 2 Diabetes—An Update for Managed Care
On-Demand Slide Lecture with Audio
Jointly sponsored by North American Center for Continuing Medical Education, LLC and Lancer Solutions, LLC
Presenters/Q&A Cohosts
David Calabrese, RPh, MHP
Chief Clinical Officer
MedMetrics Health Partners
Assistant Clinical Professor
Northeastern University Bouvé College of Pharmacy
Boston, Massachusetts
Mark E. Molitch, MD
Professor of Medicine
Division of Endocrinology, Metabolism, and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Q&A Cohosts
Andrew J. Ahmann, MD
Director, Harold Schnitzer Diabetes Health Center
Professor, Oregon Health and Science University
Portland, Oregon
Neil Minkoff, MD
Medical Director
Harvard Pilgrim Health Care
Boston, Massachusetts
Target Audience
This activity is designed for managed markets physicians and pharmacists.
Learning Objectives
After completing this activity, participants should be able to:
- Outline the pathophysiology of type 2 diabetes and treatment challenges, including disease complications
- Describe the potential role of new and emerging incretin-based type 2 diabetes pharmacotherapies in improving clinical outcomes
- Summarize data on the evidence-based and theoretical impact of incretin-based therapies on healthcare resource utilization in patients with type 2 diabetes and its chronic complications
- Apply evidence-based knowledge of disease pathophysiology and profiles of available glucose-lowering treatments to guide formulary decision making
Activity Overview
This on-demand slide lecture is available with html slides and the presentation transcript.
To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
There is no fee associated with this activity.
This educational activity is a knowledge-based activity.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this activity.
Release Date: October 13, 2009
Expiration Date: October 13, 2010
Estimated time to complete: 1 hour
For questions regarding this educational activity, please contact Angela Scarnici at 609-371-1137.
Hardware/Software Requirements
All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of North American Center for Continuing Medical Education, LLC (NACCME) and Lancer Solutions, LLC. NACCME is accredited by the ACCME to provide continuing medical education for physicians.
NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CPE Accreditation
North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-999-09-007-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.
Independent Clinical Reviewer: Simon Fisher, MD, PhD, Assistant Professor of Medicine, Cell Biology, and Physiology, Division of Endocrinology, Metabolism, and Lipid Research, Washington University, St. Louis, Missouri
Planning Committee
The planning committee comprises Andrew J. Ahmann, MD, David Calabrese, RPh, MHP, Simon Fisher, MD, PhD, Neil Minkoff, MD, Mark E. Molitch, MD; Lance Nichols, PharmD, Lancer Solutions, LLC; Kristin Dickie, Mary Johnson, Nick Lombardi, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME and Lancer Solutions, LLC, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Ahmann: Grant/Research support—Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Mannkind Corporation, Medtronic, sanofi-aventis U.S.; Consultant—Mannkind Corporation, Novo Nordisk Inc, Sensys Medical, Orexigen Therapeutics, Inc; Promotional speakers bureau—Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Merck & Co. Inc, sanofi-aventis U.S.
Dr. Fisher: Promotional speakers bureau—Merck & Co. Inc.
Dr. Molitch: Grant/Research support—Eli Lilly and Company, sanofi-aventis U.S.; Scientific advisor—MacroGenics, Inc.
Mr. Calabrese and Dr. Minkoff disclosed no relevant financial relationships with any commercial interests.
Ms. Dickie, Ms. Johnson, Mr. Lombardi, Dr. Nichols, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty has disclosed that no off-label/unapproved use(s) of drugs and/or devices will be discussed.
Privacy Policy
NACCME and Lancer Solutions, LLC protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME, Lancer Solutions, LLC, and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME and Lancer Solutions, LLC maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2009 by North American Center for Continuing Medical Education, LLC and Lancer Solutions, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education, LLC and Lancer Solutions, LLC.
Grant Support
Supported by an educational grant from Novo Nordisk Inc.
